Shares of GeneDx Holdings (WGS) plummeted 5.08% during Thursday's intraday trading session, following a significant price target cut by Wells Fargo analysts. The sharp decline comes as investors react to the downward revision in the company's valuation by a major financial institution.

Wells Fargo maintained its Hold rating on GeneDx Holdings but substantially lowered its price target from $105 to $78. This represents a 25.7% reduction in the expected value of the stock, which likely triggered a sell-off among investors. The firm also reiterated its Equal-Weight rating on the stock, suggesting a neutral stance on the company's prospects.

The market's strong negative reaction to the analyst update underscores the importance of Wall Street opinions in shaping investor sentiment. While the maintained Hold and Equal-Weight ratings indicate that Wells Fargo does not foresee immediate downside risks, the significant price target reduction implies lowered expectations for GeneDx Holdings' future performance or valuation. Investors will be closely watching for any further analyst comments or company updates that might provide more context for this valuation adjustment.